[Thyroid function in patients chronically treated with amiodarone]. 1983

A Borghi, and R G Gheri, and E Pratesi, and F Bassi, and G Cappelli, and S Paladini, and A Brocchi, and P Pucci, and F Marchi, and P F Fazzini

The effects of Amiodarone (1000-1400 mg/week, for a period ranging from 3 to 24 months) on thyroid gland function were studied in 45 patients with heart disease, using a new method of free thyroid hormone assay. Forty-four untreated patients and 11 normal subjects were used as controls. In treated patients the prevalence of dysthyroidism was 22,2% (15,6% hypothyroidism and 6,6% hyperthyroidism); the onset of dysthyroidism ranged from 20 days to 2 years after the beginning of treatment. In control patients the prevalence of dysthyroidism was 4,4% (2,2% hypothyroidism and 2,2% hyperthyroidism). In patients with hypothyroidism (TSH greater than 7 microunits/ml) T4 levels were generally low, while T3, fT4 and fT3 levels were normal. In treated patients with hyperthyroidism (fT3 greater than 5,3 pg/ml and fT4 greater than 16 pg/ml) T4 values were high, while T3 concentrations were in the normal range. In Amiodarone-treated euthyroid patients, mean T4, fT4 and rT3 values were significantly (p less than 0,01) higher than those of control subjects; TSH levels were normal in all the groups studied. These data suggest that Amiodarone can exert both a direct effect on the thyroid gland and the peripheral metabolism of thyroid hormones. The action on the thyroid gland is suggested by the high prevalence of dysthyroidism in Amiodarone-treated patients and by the high levels of T4 and fT4 observed in patients who did not show dysthyroidism. The action on the peripheral hormonal metabolism seems to be proved by the high levels of rT3 and by the prolongation of QTc interval.

UI MeSH Term Description Entries
D006980 Hyperthyroidism Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE. Hyperthyroid,Primary Hyperthyroidism,Hyperthyroidism, Primary,Hyperthyroids
D007037 Hypothyroidism A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction. Central Hypothyroidism,Primary Hypothyroidism,Secondary Hypothyroidism,TSH Deficiency,Thyroid-Stimulating Hormone Deficiency,Central Hypothyroidisms,Deficiency, TSH,Deficiency, Thyroid-Stimulating Hormone,Hormone Deficiency, Thyroid-Stimulating,Hypothyroidism, Central,Hypothyroidism, Primary,Hypothyroidism, Secondary,Hypothyroidisms,Primary Hypothyroidisms,Secondary Hypothyroidisms,TSH Deficiencies,Thyroid Stimulating Hormone Deficiency,Thyroid-Stimulating Hormone Deficiencies
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006331 Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities. Cardiac Disorders,Heart Disorders,Cardiac Diseases,Cardiac Disease,Cardiac Disorder,Heart Disease,Heart Disorder
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000638 Amiodarone An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance. Amiobeta,Amiodarex,Amiodarona,Amiodarone Hydrochloride,Amiohexal,Aratac,Braxan,Corbionax,Cordarex,Cordarone,Kordaron,L-3428,Ortacrone,Rytmarone,SKF 33134-A,Tachydaron,Trangorex,Hydrochloride, Amiodarone,L 3428,L3428,SKF 33134 A,SKF 33134A
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic

Related Publications

A Borghi, and R G Gheri, and E Pratesi, and F Bassi, and G Cappelli, and S Paladini, and A Brocchi, and P Pucci, and F Marchi, and P F Fazzini
March 1992, Recenti progressi in medicina,
A Borghi, and R G Gheri, and E Pratesi, and F Bassi, and G Cappelli, and S Paladini, and A Brocchi, and P Pucci, and F Marchi, and P F Fazzini
April 1990, Revista espanola de cardiologia,
A Borghi, and R G Gheri, and E Pratesi, and F Bassi, and G Cappelli, and S Paladini, and A Brocchi, and P Pucci, and F Marchi, and P F Fazzini
November 1984, Presse medicale (Paris, France : 1983),
A Borghi, and R G Gheri, and E Pratesi, and F Bassi, and G Cappelli, and S Paladini, and A Brocchi, and P Pucci, and F Marchi, and P F Fazzini
April 1988, Journal of endocrinological investigation,
A Borghi, and R G Gheri, and E Pratesi, and F Bassi, and G Cappelli, and S Paladini, and A Brocchi, and P Pucci, and F Marchi, and P F Fazzini
September 2000, Revista clinica espanola,
A Borghi, and R G Gheri, and E Pratesi, and F Bassi, and G Cappelli, and S Paladini, and A Brocchi, and P Pucci, and F Marchi, and P F Fazzini
October 1986, Presse medicale (Paris, France : 1983),
A Borghi, and R G Gheri, and E Pratesi, and F Bassi, and G Cappelli, and S Paladini, and A Brocchi, and P Pucci, and F Marchi, and P F Fazzini
December 1992, Journal of endocrinological investigation,
A Borghi, and R G Gheri, and E Pratesi, and F Bassi, and G Cappelli, and S Paladini, and A Brocchi, and P Pucci, and F Marchi, and P F Fazzini
January 1992, Thyroid : official journal of the American Thyroid Association,
A Borghi, and R G Gheri, and E Pratesi, and F Bassi, and G Cappelli, and S Paladini, and A Brocchi, and P Pucci, and F Marchi, and P F Fazzini
July 1978, Clinical endocrinology,
A Borghi, and R G Gheri, and E Pratesi, and F Bassi, and G Cappelli, and S Paladini, and A Brocchi, and P Pucci, and F Marchi, and P F Fazzini
January 1992, Endokrynologia Polska,
Copied contents to your clipboard!